These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

224 related articles for article (PubMed ID: 35929392)

  • 1. [Therapeutic news in Alzheimer’s disease: soon a disease-modifying therapy?].
    Villain N
    Geriatr Psychol Neuropsychiatr Vieil; 2022 Jun; 20(2):256-260. PubMed ID: 35929392
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Therapeutic news in Alzheimer's disease: Soon a disease-modifying therapy?
    Villain N
    Rev Neurol (Paris); 2022 May; 178(5):437-440. PubMed ID: 35489824
    [TBL] [Abstract][Full Text] [Related]  

  • 3. High-clearance anti-amyloid immunotherapies in Alzheimer's disease. Part 1: Meta-analysis and review of efficacy and safety data, and medico-economical aspects.
    Villain N; Planche V; Levy R
    Rev Neurol (Paris); 2022 Dec; 178(10):1011-1030. PubMed ID: 36184326
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Editorial: Targets for Disease-Modifying Therapies in Alzheimer's Disease, Including Amyloid β and Tau Protein.
    Parums DV
    Med Sci Monit; 2021 Jul; 27():e934077. PubMed ID: 34305135
    [TBL] [Abstract][Full Text] [Related]  

  • 5. High-clearance anti-amyloid immunotherapies in Alzheimer's disease. Part 2: putative scenarios and timeline in case of approval, recommendations for use, implementation, and ethical considerations in France.
    Villain N; Planche V; Levy R
    Rev Neurol (Paris); 2022 Dec; 178(10):999-1010. PubMed ID: 36336488
    [TBL] [Abstract][Full Text] [Related]  

  • 6. What's in It for Me? Contextualizing the Potential Clinical Impacts of Lecanemab, Donanemab, and Other Anti-β-amyloid Monoclonal Antibodies in Early Alzheimer's Disease.
    Jin M; Noble JM
    eNeuro; 2024 Sep; 11(9):. PubMed ID: 39332901
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Comparative efficacy, tolerability and acceptability of donanemab, lecanemab, aducanumab and lithium on cognitive function in mild cognitive impairment and Alzheimer's disease: A systematic review and network meta-analysis.
    Terao I; Kodama W
    Ageing Res Rev; 2024 Feb; 94():102203. PubMed ID: 38253184
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Alzheimer's disease: Recent treatment strategies.
    Vaz M; Silvestre S
    Eur J Pharmacol; 2020 Nov; 887():173554. PubMed ID: 32941929
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Pharmacokinetic evaluation of donanemab for the treatment of Alzheimer's.
    Song T; Wang Y; Silverglate BD; Grossberg GT
    Expert Opin Drug Metab Toxicol; 2024 Jun; 20(6):411-417. PubMed ID: 38758223
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Profiling lecanemab as a treatment option for Alzheimer's disease.
    Schiller ER; Silverglate BD; Grossberg GT
    Expert Rev Neurother; 2024 May; 24(5):433-441. PubMed ID: 38566584
    [TBL] [Abstract][Full Text] [Related]  

  • 11. [Causal treatment of Alzheimer's disease: amyloid antibodies].
    Pawlowski M; Warnecke T
    Inn Med (Heidelb); 2022 Sep; 63(9):1000-1008. PubMed ID: 35290498
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Immunotherapies Targeting Amyloid and Tau Protein in Alzheimer's Disease: Should We Move Away from Diseases and Focus on Biological Targets? A Systematic Review and Expert Opinion.
    Esquer A; Blanc F; Collongues N
    Neurol Ther; 2023 Dec; 12(6):1883-1907. PubMed ID: 37812325
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Navigating the Alzheimer's Treatment Landscape: Unraveling Amyloid-beta Complexities and Pioneering Precision Medicine Approaches.
    Patwekar M; Patwekar F; Khan S; Sharma R; Kumar D
    Curr Top Med Chem; 2024; 24(19):1665-1682. PubMed ID: 38644708
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Beyond lecanemab: Examining Phase III potential in Alzheimer's therapeutics.
    Osaka H; Nishida K; Kanazawa T
    PCN Rep; 2024 Mar; 3(1):e185. PubMed ID: 38868475
    [TBL] [Abstract][Full Text] [Related]  

  • 15. [Immunotherapies in Alzheimer's disease: state of the art and potential use in the elderly].
    Delrieu J; Ousset PJ
    Geriatr Psychol Neuropsychiatr Vieil; 2023 Jun; 21(2):233-240. PubMed ID: 37519082
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Aducanumab: The first targeted Alzheimer's therapy.
    Yang P; Sun F
    Drug Discov Ther; 2021; 15(3):166-168. PubMed ID: 34234067
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Comparative Efficacy, Tolerability, and Acceptability of Donanemab, Lecanemab, Aducanumab, Melatonin, and Aerobic Exercise for a Short Time on Cognitive Function in Mild Cognitive Impairment and Mild Alzheimer's Disease: A Systematic Review and Network Meta-Analysis.
    Terao I; Kodama W
    J Alzheimers Dis; 2024; 98(3):825-835. PubMed ID: 38461503
    [TBL] [Abstract][Full Text] [Related]  

  • 18. [Anti-amyloid Antibody Drugs as Disease-Modifying Therapies for Alzheimer's Disease].
    Sato K; Iwatsubo T
    Brain Nerve; 2024 Sep; 76(9):991-995. PubMed ID: 39251217
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Aducanumab and Its Effects on Tau Pathology: Is This the Turning Point of Amyloid Hypothesis?
    Silvestro S; Valeri A; Mazzon E
    Int J Mol Sci; 2022 Feb; 23(4):. PubMed ID: 35216126
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Donanemab: Not two without a third.
    Kurkinen M
    Adv Clin Exp Med; 2023 Oct; 32(10):1085-1087. PubMed ID: 37831471
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 12.